"The U.S. Food and Drug Administration today approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in the routine prevention of bleeding in adults and children who have a rare clotting disorder, k"...
RIXUBIS is contraindicated in patients who have:
- Known hypersensitivity to RIXUBIS or its excipients including hamster protein
- Disseminated Intravascular Coagulation (DIC) [see WARNINGS AND PRECAUTIONS]
- Signs of fibrinolysis [see WARNINGS AND PRECAUTIONS]
Last reviewed on RxList: 3/25/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Rixubis Information
Report Problems to the Food and Drug Administration
Find out what women really need.